| Autor: |
Dranko S; University of Pittsburgh Cancer Institute, PA, USA., Kinney C, Ramanathan RK |
| Jazyk: |
angličtina |
| Zdroj: |
Clinical colorectal cancer [Clin Colorectal Cancer] 2006 Sep; Vol. 6 (3), pp. 224-5. |
| DOI: |
10.3816/CCC.2006.n.040 |
| Abstrakt: |
Cetuximab is a monoclonal antibody that specifically blocks the epidermal growth factor receptor pathway. Cetuximab is now a standard drug to treat refractory advanced colorectal cancer. The most common side effect is a rash, seen in most patients. Ocular toxicity is uncommon. We report 2 cases of ocular toxicity characterized by blepharitis and conjunctivitis related to cetuximab administration. Strategies for management are discussed. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect